Avidity Biosciences (RNA) experienced a remarkable share price surge of ~900% from late 2023 to mid-2024. This is mainly due to the progress of three oligonucleotide candidates indicated for DMD, FSHD ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Avidity Biosciences, Inc. (NASDAQ:RNA) on Wednesday shared new data from participants treated continuously with del-zota for one year in the EXPLORE44 and EXPLORE44-OLE trials for Duchenne muscular ...
Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne ...
12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:RNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...
Novartis AG will acquire Avidity Biosciences, Inc. for $12bn, aiming to strengthen its neuroscience franchise and xRNA strategy with late-stage muscle disease assets. The deal brings three late-stage ...
Avidity Biosciences is on a roll—this year, the company inked a $35 million research deal with Eli Lilly and hired on a new CEO, Sarah Boyce. Now, it's reeling in $100 million in its series C round as ...
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, ...
In other recent news, Avidity Biosciences announced the successful closure of its public offering, raising $690 million in gross proceeds from the sale of 17.25 million shares at $40 per share. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results